STOP Study: Effectiveness of Zyban in a Clinical Population
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Despite the significant health, social and economic costs of cigarette smoking, 17% of
Ontarians still currently smoke. Use of smoking cessation pharmacotherapy such as Zyban
(bupropion HCl) has been shown to double quit rates but such medications are under-utilized
by smokers attempting to quit. It has been suggested that the high price of pharmacotherapy
may act as a barrier to accessing such treatment.The main objective of this study is to
evaluate the methods and effectiveness of providing smokers who want to quit with 8 weeks of
free Zyban in combination with smoking cessation counselling through family health teams and
community health centres across the province.
Hypothesis: Ontario smokers who receive 8-weeks of free bupropion in combination with brief
counselling will have higher smoking cessation rates than the standard population cessation
rates.